SciClone Pharmaceuticals (Holdings) Limited (6600.HK) Comparison with companies in other sectors?

SciClone Pharmaceuticals (Holdings) Limited has a share price of 630.30M. You can analyze SciClone Pharmaceuticals (Holdings) Limited (6600.HK) competitors across different market sectors through stock heatmaps.

What are 6600.HK's NET and operating margins?

SciClone Pharmaceuticals (Holdings) Limited (6600.HK) operating margin is around 0.38, and net profit margin is approximately 0.36 as of the latest reports.

In what way does 6600.HK's earnings per share (EPS) trend reflect its financial momentum?

SciClone Pharmaceuticals (Holdings) Limited (6600.HK) EPS is 1.85 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for SciClone Pharmaceuticals (Holdings) Limited is 10.12, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for SciClone Pharmaceuticals (Holdings) Limited?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for SciClone Pharmaceuticals (Holdings) Limited like P/E which is 9.42, P/B which is 3.24, and PEG which is 0.10. Compare them with sector averages to evaluate if the stock is priced fairly.

SciClone Pharmaceuticals (Holdings) Limited

6600.HK•HKSE

Healthcare

Drug Manufacturers - Specialty & Generic

HK$18.72

HK$0.16(0.86%)

SciClone Pharmaceuticals (Holdings) Limited (6600.HK) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$1.85

P/E Ratio

10.12

ROE

0.36%

Net Margin

0.36%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$11.80B

Shares OutstandingTotal number of shares issued

$630.30M

Book Value/ShareNet worth per share

$5.31

Revenue/ShareAnnual revenue per share

$5.13

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$1.85

Net MarginNet income as percentage of revenue

35.55%

Operating MarginOperating income as percentage of revenue

38.19%

ROEReturn on shareholders' equity

35.86%

ROAReturn on total assets

28.05%

ROCEReturn on capital employed

36.50%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$2.16

Cash/ShareCash and equivalents per share

$3.62

FCF YieldFree cash flow as percentage of market cap

12.25%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 6600.HKFinancial Ratios Analysis details for 6600.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 6600.HKSector Benchmarking details for 6600.HK are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for SciClone Pharmaceuticals (Holdings) Limited Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of SciClone Pharmaceuticals (Holdings) Limited. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account SciClone Pharmaceuticals (Holdings) Limited's unique business strengths and challenges.

Key Financial Metrics for SciClone Pharmaceuticals (Holdings) Limited

For SciClone Pharmaceuticals (Holdings) Limited, essential financial indicators include EPS 1.85, PE 10.12, and ROE 0.36. These key ratios reveal insights into SciClone Pharmaceuticals (Holdings) Limited's profitability, valuation, and operational health. Understanding these metrics enables you to compare SciClone Pharmaceuticals (Holdings) Limited with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of SciClone Pharmaceuticals (Holdings) Limited

Metrics like Net Margin 35.55% and ROA 28.05% shed light on how well SciClone Pharmaceuticals (Holdings) Limited is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether SciClone Pharmaceuticals (Holdings) Limited can sustain its operations and continue growing in the future.

Valuation and Market Position of SciClone Pharmaceuticals (Holdings) Limited

Using ratios such as P/B Ratio 3.24 and PEG Ratio 0.10, investors can assess whether SciClone Pharmaceuticals (Holdings) Limited is appropriately valued based on its financials and growth potential. These figures, combined with SciClone Pharmaceuticals (Holdings) Limited's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for SciClone Pharmaceuticals (Holdings) Limited

Financial health indicators, such as Debt/Equity Ratio 0.01 and Cash Flow $2.16, provide a snapshot of SciClone Pharmaceuticals (Holdings) Limited's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like SciClone Pharmaceuticals (Holdings) Limited, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for SciClone Pharmaceuticals (Holdings) Limited

Investing in SciClone Pharmaceuticals (Holdings) Limited based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at SciClone Pharmaceuticals (Holdings) Limited focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;